Galecto Inc expected to post a loss of 47 cents a share - Earnings Preview

Damora Therapeutics

03/11/2023 12:26

* Galecto Inc  GLTO.OQ   GLTO.O  is expected to show no
change in
quarterly revenue when it reports  results 
    * 
    * ​Refinitiv's mean analyst estimate for Galecto Inc is for
a loss
of 47 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Galecto Inc
is
$3.5​, above​ its last closing price of $0.54. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -0.59       -0.59      -0.41     Beat    30.1
 Mar. 31 2023  -0.61       -0.62      -0.51     Beat    18.4
 Dec. 31 2022  -0.57       -0.57      -0.55     Beat    3.5​
 Sep. 30 2022  -0.68       -0.68      -0.54     Beat    20.6
 ​​Jun.        -0.69       -0.69      -0.67     Beat    2.9
 30 2022                                                
                                                        ​
 Dec. 31 2021  -0.56       -0.56      -0.53     Beat    5.4
 Sep. 30 2021              -0.56      -0.50     Beat    10.7
 This summary was machine generated November 3 at 12:26 GMT.  All
figures in US dollars  unless otherwise stated